Search results for " payment system"

showing 7 items of 7 documents

Clinical and economic impact of drug eluting beads in transarterial chemoembolization for hepatocellular carcinoma

2015

Summary What is known and objective Drug eluting beads (DEBs) theoretically improve the efficacy and safety of transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC). Nonetheless, their economic profile has not been assessed. Our retrospective before/after study aimed to compare efficacy, safety and economic profile of two strategies of TACE without (Period 1) or with the possibility of using DEBs (Period 2). Methods All HCC patients treated by TACE in our hospital between March 2006 and May 2013 were included. Economic analyses were performed from the French Public Health Insurance point of view according to the French Diagnosis-Related Group prospective payment system an…

AdultMalesafetymedicine.medical_specialtyCarcinoma HepatocellularCost effectivenesschemoembolisationCost-Benefit AnalysisAntineoplastic AgentsTreatment failureDrug CostsEthiodized OilInternal medicinemedicineOverall survivalHumansPharmacology (medical)Chemoembolization Therapeuticcost-effectivenessAgedRetrospective StudiesPharmacologyAged 80 and overDrug CarriersDrug eluting beadsPublic health insurancebusiness.industryLiver NeoplasmsMiddle Agedmedicine.diseasePrognosisMicrospheres3. Good healthSurgerySurvival RateTreatment OutcomeMedian timeDoxorubicinHepatocellular carcinoma[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/PharmacologyFemaleProspective payment systembusinessIdarubicin
researchProduct

[Cost of hospital-based management of acute myeloid leukemia: from analytical to procedure-based tarification]

2006

International audience; The confrontation of the macro- and micro-economic approaches of hospital costs is a recurrent question, in particular for pathologies where length of stay is highly variable, like acute myeloid leukemias (AML). This monocentric and retrospective study compares direct hospital medical costs of induction and relapse treatment sequences for AML, valued according to four different approaches: the analytic accounting system of our hospital, the French Diagnosis Related Group (DRG) cost databases of hospital discharges (readjusted, or not, to actual hospital stay duration), and official tariffs from the new French DRG prospective payment system. The average cost of hospit…

MaleMESH: Remission InductionMESH : Retrospective StudiesMESH : RecurrenceMESH: Leukemia MyeloidMESH: Length of StayRecurrence[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyMESH : FemaleHospital Costshealth care economics and organizationsMESH: Diagnosis-Related GroupsMESH: Hospital CostsMESH: Middle AgedRemission InductionMESH : Acute DiseaseMiddle AgedMESH : AdultMESH : Diagnosis-Related GroupsMESH : Length of StayLeukemia MyeloidAcute DiseaseMESH : Leukemia MyeloidMESH: Acute Disease[SDV.IMM]Life Sciences [q-bio]/ImmunologyFemaleMESH : Prospective Payment SystemFranceAdultAdolescent[SDV.IMM] Life Sciences [q-bio]/ImmunologyMESH : MaleMESH : Hospital CostsMESH: Prospective Payment SystemMESH : AdolescentHumansMESH : Middle AgedMESH : FranceDiagnosis-Related GroupsRetrospective StudiesMESH: AdolescentMESH : Remission InductionMESH: HumansProspective Payment SystemMESH : HumansMESH: Retrospective StudiesMESH: AdultLength of StayMESH: MaleMESH: RecurrenceMESH: FranceMESH: Female
researchProduct

Result and cost of hepatic chemoembolisation with drug eluting beads in 21 patients.

2012

Abstract Purpose The aim of our study was to assess the results and cost of a treatment strategy involving transarterial chemoembolisation with drug eluting beads (DEB-TACE) in patients with unresectable non-metastatic hepatocellular carcinoma (HCC). Patients and methods This study included all patients treated with DEB-TACE in our hospital between January 2009 and December 2010. All patients received DEB-TACE on demand and were evaluated after each session. Results Twenty-one patients received an average of 1.3 sessions. The median time to treatment discontinuation and median progression-free survival was 181 days and 295 days, respectively. Toxicity caused treatment discontinuation in thr…

Malemedicine.medical_specialtyCarcinoma HepatocellularHepatocellular carcinomaCostResultDrug Delivery SystemsTransarterial chemoembolisationOn demandmedicineHumansRadiology Nuclear Medicine and imagingIn patientChemoembolization TherapeuticAgedRetrospective StudiesAged 80 and overRadiological and Ultrasound TechnologyDrug eluting beadsbusiness.industryLiver NeoplasmsGeneral MedicineDirect costMiddle Agedmedicine.diseaseDrug eluting beadsMicrospheresSurgeryDiscontinuationTreatment OutcomeMedian timeHepatocellular carcinomaCosts and Cost AnalysisFemaleProspective payment systembusinessDiagnostic and interventional imaging
researchProduct

A Multimodal Technique for an Embedded Fingerprint Recognizer in Mobile Payment Systems

2009

The development and the diffusion of distributed systems, directly connected to recent communication technologies, move people towards the era of mobile and ubiquitous systems. Distributed systems make merchant-customer relationships closer and more flexible, using reliable e-commerce technologies. These systems and environments need many distributed access points, for the creation and management of secure identities and for the secure recognition of users. Traditionally, these access points can be made possible by a software system with a main central server. This work proposes the study and implementation of a multimodal technique, based on biometric information, for identity management a…

Settore ING-INF/05 - Sistemi Di Elaborazione Delle InformazioniMinutiaeAuthenticationUbiquitous authentication multimodal systems mobile payment systems biometric techniques and embedded systemsBiometricsComputer Networks and Communicationsbusiness.industryComputer scienceFingerprint (computing)Process (computing)TK5101-6720Identity managementComputer Science ApplicationsEmbedded systemTelecommunicationMobile paymentSoftware systembusinessComputer networkMobile Information Systems
researchProduct

L’evoluzione del sistema dei pagamenti in Italia: configurazioni strutturali e profili di integrazione finanziaria

2019

Un corretto ed ordinato sistema dei pagamenti costituisce condizione essenziale per la stabilità e l’efficienza del sistema finanziario, per il buon funzionamento dei mercati e per la conduzione della politica monetaria. L’intero sistema dei pagamenti italiano è evoluto in direzione di più elevati livelli di efficienza ed efficacia, in un contesto di progressiva armonizzazione e cooperazione sovranazionale, quale condizione per lo sviluppo di un sistema integrato dei pagamenti europeo; il presente articolo pertanto delinea, seppure a grandi linee, il quadro evolutivo del sistema dei pagamenti nazionale, avuto riguardo agli aspetti istituzionali, economico-finanziari e regolamentari. This pa…

Settore SECS-P/11 - Economia Degli Intermediari Finanziaribanking payment system payment instrument money financial integration financial system central bank bank supervision.banca sistema dei pagamenti strumento di pagamento moneta integrazione finanziaria sistema finanziario banca centrale supervisione bancaria.
researchProduct

Debating Sound Money in Early Modern Europe: From Dualist to Metallic Monetary Systems

2019

International audience; In this paper, we present the monetary debates in Europe from the XVIth to the XVIIIth centuries from the viewpoint of the problem of good and sound money. The framework of the paper is built on a typology of monetary systems, by which a dualist system is distinguished from a metallic one. Under the dualist system, the value in units of account of the specie in circulation was defined by monetary proclamations (Einaudi locates this era from Charlemagne to the French Revolution). Metallist proponents aimed at preventing any kind of manipulations with a radical transformation of the system of payment, which gave birth to a metallic monetary system from the very end of …

Value (ethics)JEL: B - History of Economic Thought Methodology and Heterodox Approaches/B.B1 - History of Economic Thought through 1925/B.B1.B11 - Preclassical (Ancient Medieval Mercantilist Physiocratic)060106 history of social sciencesmedia_common.quotation_subjectmonetary systems0502 economics and businesssound moneyEconomics0601 history and archaeologyCirculation (currency)JEL: E - Macroeconomics and Monetary Economics/E.E4 - Money and Interest Rates/E.E4.E42 - Monetary Systems • Standards • Regimes • Government and the Monetary System • Payment SystemsMonetary history050207 economics[SHS.ECO] Humanities and Social Sciences/Economics and Financemedia_commonmetallismJEL: N - Economic History/N.N1 - Macroeconomics and Monetary Economics • Industrial Structure • Growth • Fluctuations/N.N1.N13 - Europe: Pre-1913dualist systemMetallismhistory of monetary thoughtKeynesian economics05 social sciences06 humanities and the artsCapitalismPaymentMonetary system[SHS.ECO]Humanities and Social Sciences/Economics and FinanceEuropeMercantilismEarly modern Europe
researchProduct

Appropriate cytotoxic drugs usages in solid tumors: Impact of appropriate use referentials

2012

Summary Background The appropriate use of anticancer drugs is at major stake of steering health facilities. French health authorities have specifically elaborated evidence-based principles and guidelines on good practice for the management of anticancer drugs called “referentiels de bon usage” (RBU in French). Objectives The primary aim of the survey is to confront therapeutic practices and PGU. The secondary objective is to evaluate the impact of PGU on “outside the prescribing guidelines” therapeutic use, as compared with a similar study conducted in 2004. Patients and methods The survey was conducted from 1st July 2008 to 31st March 2009 at two reference centers in cancer research, and i…

medicine.medical_specialtybusiness.industryAlternative medicineEvidence-based medicineDiseaseAppropriate useAnticancer drugScientific evidencemedicinePharmacology (medical)Prospective payment systemIntensive care medicineGood practicebusinessLe Pharmacien Hospitalier et Clinicien
researchProduct